CRC (colorectal cancer) is cancer of the colon or rectum that typically develops from abnormal mucosal growths and can spread if untreated.
Moleculin said its MIRACLE Phase 2B/3 AML trial is nearing first unblinding, with blinded CRc above 40% and CR around 30%. The first 45-subject readout is expected before June 30, 2026.
Recent advances in genetic science are shifting colorectal cancer screening toward direct detection of DNA changes. In India, CRC is now the fourth most common cancer, with more than 64,000 new cases and over 38,000 deaths reported in 2022.
Adagene and Incyte will collaborate on a Phase 1 study combining muzastotug with INCA33890 for MSS colorectal cancer patients, beginning in 2026. The collaboration marks the second instance where Adagene's SAFEbody technology is paired with a PD-1-based bispecific. Muzastotug has shown encouraging response rates in combination with pembrolizumab in previous trials.
The phase 3 ENVISION trial shows 80% complete response rate for novel bladder cancer chemoablative therapy. AI integration accelerates precision oncology through biomarker identification and targeted treatments. OncoPRO real-time symptom monitoring system enhances patient safety and clinical trial data capture.
Summit Therapeutics will participate in three investor conferences in March 2026, following FDA acceptance of its BLA for ivonescimab in lung cancer with a PDUFA date of November 14, 2026.
New combination therapies demonstrate improved outcomes in advanced anal and colorectal cancers, with retifanlimab plus chemotherapy approved for anal cancer and onvansertib showing strong efficacy signals in RAS-mutated colorectal cancer.
Researchers at Stony Brook University developed an oral vaccine using modified Listeria monocytogenes that generates anti-tumor immune responses in the gut and significantly improves colorectal cancer control when combined with checkpoint inhibitors.
Moleculin Biotech announced a preliminary blinded composite complete remission rate of 40% in the first 30 subjects of its Phase 2B/3 MIRACLE trial testing Annamycin plus cytarabine for relapsed or refractory acute myeloid leukemia.
Pfizer announced positive progression-free survival results from the BREAKWATER trial evaluating Braftovi in combination with cetuximab and Folfiri in previously untreated metastatic colorectal cancer patients with BRAF V600E mutation.
New research identifies circulating tumor-reactive T cell characteristics and inflammatory biomarkers as predictive indicators for immune checkpoint inhibitor response in cancer patients, while the PD-L1 testing market is projected to reach $36.44 billion by 2032.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07511972 |
Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies |
WITHDRAWN | PHASE2 |
| NCT07397338 |
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
| NCT07381309 |
Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM |
NOT_YET_RECRUITING | PHASE2 |
| NCT07349537 |
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors |
RECRUITING | PHASE1 |
| NCT07321106 |
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer |
RECRUITING | PHASE1 |
| NCT07283367 |
A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. |
RECRUITING | PHASE1/PHASE2 |
| NCT07204574 |
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer |
RECRUITING | PHASE1/PHASE2 |
| NCT06728072 |
Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer |
RECRUITING | PHASE2 |
| NCT06682793 |
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression |
RECRUITING | PHASE1/PHASE2 |
| NCT06657222 |
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors |
RECRUITING | PHASE1/PHASE2 |
